Provision of essential amino acid precursors

The provision of essential amino acid precursors is a therapeutic and physiological process rather than a specific molecular target like a receptor or enzyme. It involves the supply of the nine amino acids that humans cannot synthesize de novo—histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine—which are required for protein synthesis, tissue repair, and the production of neurotransmitters (National Research Council, 2005). In clinical settings, this is typically achieved through specialized enteral or parenteral nutrition for patients suffering from severe malabsorption, critical illness, or catabolic states such as cancer cachexia (StatPearls, 2023). This 'target' is primarily relevant in the management of inborn errors of metabolism, where specific precursors must be provided to circumvent blocked metabolic pathways, such as providing tyrosine to patients with phenylketonuria (NIH, 2022). While essential for survival, the term refers to a nutritional strategy and pharmacological intervention of providing metabolites rather than a distinct protein target. Excessive or imbalanced provision of these precursors can lead to significant safety concerns, including hyperammonemia and metabolic acidosis, particularly in patients with impaired renal or hepatic function (PubMed, 2021). Therefore, it is classified as an incorrect entry for a specific therapeutic target molecule.

Other names

Amino acid supplementationEssential amino acid deliveryNutritional support of amino acidsParenteral amino acid therapy

The direct administration of amino acids bypasses de novo synthesis or digestive limitations, providing the necessary building blocks for translation and systemic metabolic processes.